We also identified the differential interaction between JAK1 and STAT3 with PRIDE, where evidence in the literature reports that JAK inhibitors can decrease the activation of STATs, and their interaction has been demonstrated as a viable target for drug development, such as AZD1480 for inhibiting the growth of GBM tumors. Here, STAT3 is linked to glioblastoma.